UK markets closed

Vericel Corporation (VCEL)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
43.74-0.12 (-0.27%)
At close: 04:00PM EDT
43.74 0.00 (0.00%)
After hours: 04:20PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close43.86
Open43.67
Bid37.04 x 100
Ask43.81 x 100
Day's range42.38 - 44.50
52-week range29.24 - 53.05
Volume522,006
Avg. volume468,392
Market cap2.116B
Beta (5Y monthly)1.73
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance

    Full-Year 2023 Total Revenue Growth of 20% to $197.5 Million, with Adjusted EBITDA Growth of 40% Fourth Quarter Total Revenue Growth of 23% to $65.0 Million, with Adjusted EBITDA Growth of 50% Fourth Quarter Gross Margin of 75% and Adjusted EBITDA Margin of 34% Full-Year 2024 Total Revenue Guidance of $237 to $241 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sport

  • GlobeNewswire

    Vericel to Present at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024

    CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO and Joe Mara, CFO will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference at 11:10 a.m. ET on Tuesday, March 5, 2024. A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: htt

  • GlobeNewswire

    Vericel to Report Fourth-Quarter and Full-Year 2023 Financial Results on February 29, 2024

    CAMBRIDGE, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its fourth-quarter and full-year 2023 financial results on Thursday, February 29, 2024. Vericel’s management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights. The live webcast can be accessed on the Investor Relations section